Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
evidence of the efficacy of bevacizumab in patients with HHT.Both cases also show that symptoms and transfusion requirements improve with this therapy, without an appreciable change in arteriovenous malformations.Like Oosting et al., we found no difference in the size of our patient's pulmonary arteriovenous malformations on CT before and after bevacizumab.Their experience demonstrates the long-term safety and tolerability of bevacizumab in such patients.Our patient continues to report symptomatic benefit more than a year after completing therapy, and he has required only one intravenous infusion of iron during this time.His hemoglobin levels have remained stable at 14 to 15 g per deciliter.The cost of our patient's regimen (a total of 30 mg per kilogram over four cycles) would be approximately $12,000 today.The costs of continuing the drug in the long term, especially without a Food and Drug Administration-approved indication, would be prohibitive.Our case shows that intermittent dosing allows for long-term, symptomatic improvement and stability of pulmonary arteriovenous malformations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this patient, RDN resulted in a progressive decrease in blood pressure from 161/107 mmHg at baseline to 127/81 mmHg at 12-month follow-up.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“However, RDN-induced reductions in MSNA18 and beneficial effects of RDN on conditions that are not traditionally thought to be driven by the kidney, including heart failure and arrthymia19, cannot be wholly explained by alterations in body fluid homeostasis.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“ablation of the renal nerves was also associated with a substantial decrease in muscle sympathetic nerve activity (MSNA), from 56 bursts per minute before RDN to 19 bursts per minute at 12 months after the procedure.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“The hypothesis that renal afferents mediate some of the BP effects of RDN in humans was sparked by the finding that whole-body noradrenaline spillover and MSNA were decreased in a single patient 1 year after RDN170.”
From Obesity, kidney dysfunction and hypertension: mechanistic links (2019) · cites this paper as [170]
Citations
Cites
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Self-citationNeural control of renal function
DiBona, G. F., & Kopp, U. C. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.1.75 · Cited by 1,212
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132
Schlaich, M. P., Lambert, E., Kaye, D. M., Krozowski, Z., Campbell, D. J., Lambert, G., Hastings, J., Aggarwal, A., & Esler, M. D. (2004) · Hypertension · doi:10.1161/01.hyp.0000103160.35395.9e · Cited by 514
Self-citationNoradrenaline Release and the Pathophysiology of Primary Human Hypertension
Esler, M., Jennings, G., & Lambert, G. (1989) · American Journal of Hypertension · doi:10.1093/ajh/2.3.140s · Cited by 138
Self-citation
Cited by
Mechanisms of Diabetic Complications
Forbes, J. M., & Cooper, M. E. (2013) · Physiological Reviews · doi:10.1152/physrev.00045.2011 · Cited by 2,890
“Recently, successful targeting of the sympathetic nervous system as a hypotensive strategy by bilateral renal denervation has been examined (315, 521).”
BackgroundObesity-Induced Hypertension: Interaction of Neurohumoral and Renal Mechanisms
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2015) · Circulation Research · doi:10.1161/circresaha.116.305697 · Cited by 1,360
Neural Control of Renal Function*
Kopp, U. C., & DiBona, G. F. (2020) · Reflex Control of the Circulation · doi:10.1201/9780367813338-17 · Cited by 1,126
Role of the Autonomic Nervous System in Atrial Fibrillation: Pathophysiology and Therapy
Chen, P.-S., Chen, L. S., Fishbein, M. C., Lin, S.-F., & Nattel, S. (2014) · Circulation Research · doi:10.1161/circresaha.114.303772 · Cited by 790
“Other work showed that renal sympathetic denervation can reduce sympathetic nerve activity.(127) Because sympathetic nerve activity is important in blood pressure control,(76,85) reduction of sympathetic outflow may, in part, explain the reduction of blood pressure in some patients.”
BackgroundKandzari, D. E., Böhm, M., Mahfoud, F., Townsend, R. R., Weber, M. A., Pocock, S., Tsioufis, K., Tousoulis, D., Choi, J. W., East, C., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30951-6 · Cited by 793
Symplicity HTN-1 Investigators (2011) · Hypertension · doi:10.1161/hypertensionaha.110.163014 · Cited by 744
Sympathetic Nervous System Overactivity and Its Role in the Development of Cardiovascular Disease
Malpas, S. C. (2010) · Physiological Reviews · doi:10.1152/physrev.00007.2009 · Cited by 699
Obesity, kidney dysfunction and hypertension: mechanistic links
Hall, J. E., do Carmo, J. M., da Silva, A. A., Wang, Z., & Hall, M. E. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0145-4 · Cited by 654
The Autonomic Nervous System and Hypertension
Mancia, G., & Grassi, G. (2014) · Circulation Research · doi:10.1161/circresaha.114.302524 · Cited by 627
Krum, H., Schlaich, M. P., Sobotka, P. A., Böhm, M., Mahfoud, F., Rocha-Singh, K., Katholi, R., & Esler, M. D. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62192-3 · Cited by 619
Self-citationThe Sympathetic Nervous System Alterations in Human Hypertension
Grassi, G., Mark, A., & Esler, M. (2015) · Circulation Research · doi:10.1161/circresaha.116.303604 · Cited by 616
Self-citationThe Autonomic Nervous System and Heart Failure
Florea, V. G., & Cohn, J. N. (2014) · Circulation Research · doi:10.1161/circresaha.114.302589 · Cited by 572
The human sympathetic nervous system: its relevance in hypertension and heart failure
Parati, G., & Esler, M. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs041 · Cited by 538
Self-citationBrandt, M. C., Mahfoud, F., Reda, S., Schirmer, S. H., Erdmann, E., Böhm, M., & Hoppe, U. C. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.034 · Cited by 501
“Furthermore, whole-body sympathetic activation is reduced by the ablation of afferent renal nerves, which stimulate sympathetic outflow in the hypothalamus (9,34).”
BackgroundEsler, M. D., Krum, H., Schlaich, M., Schmieder, R. E., Böhm, M., & Sobotka, P. A. (2012) · Circulation · doi:10.1161/circulationaha.112.130880 · Cited by 461
Self-citationWitkowski, A., Prejbisz, A., Florczak, E., Kądziela, J., Śliwiński, P., Bieleń, P., Michałowska, I., Kabat, M., Warchoł, E., Januszewicz, M., et al. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.173799 · Cited by 460
Self-citationCardiorenal Syndrome: New Perspectives
Bock, J. S., & Gottlieb, S. S. (2010) · Circulation · doi:10.1161/circulationaha.109.886473 · Cited by 455
Pokushalov, E., Romanov, A., Corbucci, G., Artyomenko, S., Baranova, V., Turov, A., Shirokova, N., Karaskov, A., Mittal, S., & Steinberg, J. S. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.05.036 · Cited by 432
“blood pressure control (5), at least in part by reducing central nervous system sympathetic output (6,7).”
BackgroundTranslational medicine: the antihypertensive effect of renal denervation
DiBona, G. F., & Esler, M. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00647.2009 · Cited by 432
Self-citationRenal Denervation in Moderate to Severe CKD
Hering, D., Mahfoud, F., Walton, A. S., Krum, H., Lambert, G. W., Lambert, E. A., Sobotka, P. A., Böhm, M., Cremers, B., Esler, M. D., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011111062 · Cited by 361
Self-citationHering, D., Lambert, E. A., Marusic, P., Walton, A. S., Krum, H., Lambert, G. W., Esler, M. D., & Schlaich, M. P. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.00194 · Cited by 356
“Bilateral RDN was performed in 1 session using a radiofrequency catheter (Simplicity; Medtronic Ardian Inc, Palo Alto, CA) introduced into each renal artery via femoral access as described previously.(14,15,17) To minimize local visceral pain during the energy delivery, anxiolytics and analgesics were administered int…”
MethodSelf-citationLambert, G. W., Straznicky, N. E., Lambert, E. A., Dixon, J. B., & Schlaich, M. P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.002 · Cited by 347
Self-citationMahfoud, F., Böhm, M., Schmieder, R., Narkiewicz, K., Ewen, S., Ruilope, L., Schlaich, M., Williams, B., Fahy, M., & Mancia, G. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz118 · Cited by 297
Self-citationThe Carotid Body as a Therapeutic Target for the Treatment of Sympathetically Mediated Diseases
Paton, J. F. R., Sobotka, P. A., Fudim, M., Engelman, Z. J., Hart, E. C. J., McBryde, F. D., Abdala, A. P., Marina, N., Gourine, A. V., Lobo, M., et al. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.00064 · Cited by 310
“Reduction of blood pressure after dorsal rhizotomy in rats with renal hypertension and reduced total body noradrenaline and muscle sympathetic nerve activity in humans after renal denervation confirm that the afferent signals from the kidney underlie some of the excessive sympathetic drive seen in these states.(13,14)…”
BackgroundSelf-citationKandzari, D. E., Bhatt, D. L., Sobotka, P. A., O'Neill, W. W., Esler, M., Flack, J. M., Katzen, B. T., Leon, M. B., Massaro, J. M., Negoita, M., et al. (2012) · Clinical Cardiology · doi:10.1002/clc.22008 · Cited by 310
Self-citationMahfoud, F., Cremers, B., Janker, J., Link, B., Vonend, O., Ukena, C., Linz, D., Schmieder, R., Rump, L. C., Kindermann, I., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.193870 · Cited by 303
“marked and sustained blood pressure reductions, RD has also been shown to reduce renal norepinephrine spillover(9) and muscle sympathetic nerve activity(11) and to improve glucose metabolism in patients with resistant hypertension.(10,12,13)”
BackgroundSelf-citationNeural Control of Renal Function
Johns, E. J., Kopp, U. C., & DiBona, G. F. (2011) · Comprehensive Physiology · doi:10.1002/cphy.c100043 · Cited by 278
The sympathetic nervous system and blood pressure in humans: implications for hypertension
Fisher, J. P., & Paton, J. F. R. (2012) · Journal of Human Hypertension · doi:10.1038/jhh.2011.66 · Cited by 260
Mahfoud, F., Ukena, C., Schmieder, R. E., Cremers, B., Rump, L. C., Vonend, O., Weil, J., Schmidt, M., Hoppe, U. C., Zeller, T., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000949 · Cited by 254
“Renal denervation offers a novel and well-tolerated approach to selectively interrupt sympathetic fibers and effectively reduce systolic and diastolic office BP.11,12 Recently, concerns have been raised that RDN might not reduce ABP equally effectively.22 The results of the present multi-center study in >300 patients…”
BackgroundInfluentialSelf-citationRenal Denervation as a Therapeutic Approach for Hypertension: Novel Implications for an Old Concept
Schlaich, M. P., Sobotka, P. A., Krum, H., Whitbourn, R., Walton, A., & Esler, M. D. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.138610 · Cited by 249
Self-citationEsler, M. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00832.2009 · Cited by 243
Self-citationSympathetic Nervous System and Hypertension
DiBona, G. F. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.00633 · Cited by 238
Linz, D., Mahfoud, F., Schotten, U., Ukena, C., Neuberger, H.-R., Wirth, K., & Böhm, M. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.191965 · Cited by 227
Renal sympathetic denervation for treatment of electrical storm: first-in-man experience
Ukena, C., Bauer, A., Mahfoud, F., Schreieck, J., Neuberger, H.-R., Eick, C., Sobotka, P. A., Gawaz, M., & Böhm, M. (2012) · Clinical Research in Cardiology · doi:10.1007/s00392-011-0365-5 · Cited by 223
“There is substantial data suggestive of reduction of systemic sympathetic activity in patients with resistant hypertension who undergo RDN [10, 11].”
BackgroundSelf-citationKatholi, R. E., & Couri, D. M. (2011) · International Journal of Hypertension · doi:10.4061/2011/495349 · Cited by 219
Chiang, C.-E., Wang, T.-D., Ueng, K.-C., Lin, T.-H., Yeh, H.-I., Chen, C.-Y., Wu, Y.-J., Tsai, W.-C., Chao, T.-H., Chen, C.-H., et al. (2015) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2014.11.005 · Cited by 199
Role of the Sympathetic Nervous System and Its Modulation in Renal Hypertension
Sata, Y., Head, G. A., Denton, K., May, C. N., & Schlaich, M. P. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00082 · Cited by 188
“org March 2018 | Volume 5 | Article 82 Increased RSNA has been demonstrated to contribute to the rise in blood pressure through three major mechanisms which include: (1) an increase in tubular reabsorption of urinary sodium and water, (2) a reduction of renal blood flow and glomerular filtration rate (GFR), and (3) re…”
InfluentialSelf-citationKumagai, H., Oshima, N., Matsuura, T., Iigaya, K., Imai, M., Onimaru, H., Sakata, K., Osaka, M., Onami, T., Takimoto, C., et al. (2012) · Hypertension Research · doi:10.1038/hr.2011.208 · Cited by 184
Sympatho-renal axis in chronic disease
Sobotka, P. A., Mahfoud, F., Schlaich, M. P., Hoppe, U. C., Böhm, M., & Krum, H. (2011) · Clinical Research in Cardiology · doi:10.1007/s00392-011-0335-y · Cited by 179
“hypertension patients without evident renal disease suggest the renal chemo- or baroreceptors are responding to stimuli other than overt renal damage, possibly local metabolites of ischemia or hypoxia [14].”
BackgroundSelf-citationPressure natriuresis and the renal control of arterial blood pressure
Ivy, J. R., & Bailey, M. A. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2014.271676 · Cited by 177
“The initial results were promising, with a 30 mmHg reduction in office BP being reported at 9–12 months (Krum et al. 2009; Schlaich et al. 2009; Esler et al. 2010), persisting to 36 months in the follow-up for Symplicity HTN-1 (Krum et al.”
BackgroundBooth, L. C., Nishi, E. E., Yao, S. T., Ramchandra, R., Lambert, G. W., Schlaich, M. P., & May, C. N. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04176 · Cited by 171
Self-citationBrinkmann, J., Heusser, K., Schmidt, B. M., Menne, J., Klein, G., Bauersachs, J., Haller, H., Sweep, F. C., Diedrich, A., Jordan, J., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.201186 · Cited by 166
“over have been reported in a single patient after renal nerve ablation.(10) Similarly, removal of the diseased native kidney reduced MSNA in renal transplant recipients.”
BackgroundThe sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target?
Lansdown, A., & Rees, D. A. (2012) · Clinical Endocrinology · doi:10.1111/cen.12003 · Cited by 165
Geisler, B. P., Egan, B. M., Cohen, J. T., Garner, A. M., Akehurst, R. L., Esler, M. D., & Pietzsch, J. B. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.029 · Cited by 159
“This denervation reduces sympathetic renal and central tonus (4) and arterial blood pressure (5,6).”
BackgroundSelf-citationThe ‘neuroadrenergic hypothesis’ in hypertension: current evidence
Grassi, G. M., Seravalle, G., & Quarti‐Trevano, F. (2009) · Experimental Physiology · doi:10.1113/expphysiol.2009.047381 · Cited by 159
“The two approaches currently used are the renal denervation procedure, using a radiofrequency catheter, and chronic carotid baroreceptor stimulation via implantation of an electric device (Schlaich et al. 2009; Wustmann et al. 2009).”
MethodSchlaich, M. P., Bart, B., Hering, D., Walton, A., Marusic, P., Mahfoud, F., Böhm, M., Lambert, E. A., Krum, H., Sobotka, P. A., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.01.218 · Cited by 155
Self-citationMicro‐anatomy of the renal sympathetic nervous system: A human postmortem histologic study
Atherton, D. S., Deep, N. L., & Mendelsohn, F. O. (2012) · Clinical Anatomy · doi:10.1002/ca.21280 · Cited by 157
Jordan, J., Yumuk, V., Schlaich, M., Nilsson, P. M., Zahorska-Markiewicz, B., Grassi, G., Schmieder, R. E., Engeli, S., & Finer, N. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283537347 · Cited by 154
“The response may be mediated in part through ablation of renal afferent nerves decreasing centrally generated sympathetic activity [101].”
BackgroundSelf-citationNew drugs, procedures, and devices for hypertension
Laurent, S., Schlaich, M. P., & Esler, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60825-3 · Cited by 159
Self-citationMicroglia Participate in Neurogenic Regulation of Hypertension
Shen, X. Z., Li, Y., Li, L., Shah, K. H., Bernstein, K. E., Lyden, P., & Shi, P. (2015) · Hypertension · doi:10.1161/hypertensionaha.115.05333 · Cited by 146
Hering, D., Marusic, P., Walton, A. S., Lambert, E. A., Krum, H., Narkiewicz, K., Lambert, G. W., Esler, M. D., & Schlaich, M. P. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.03098 · Cited by 142
“Bilateral RDN was performed using a radiofrequency ablation catheter (Symplicity; Medtronic Ardian Inc, Palo Alto, CA), as described previously.(15,16,19)”
MethodSelf-citationDevice-Based Antihypertensive Therapy: Therapeutic Modulation of the Autonomic Nervous System
Krum, H., Sobotka, P. A., Mahfoud, F., Böhm, M., Esler, M., & Schlaich, M. P. (2011) · Circulation · doi:10.1161/circulationaha.110.971580 · Cited by 158
Self-citationEsler, M., Lambert, E., & Schlaich, M. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00182.2010 · Cited by 141
Self-citationRenal denervation: a potential new treatment modality for polycystic ovary syndrome?
Schlaich, M. P., Straznicky, N., Grima, M., Ika-Sari, C., Dawood, T., Mahfoud, F., Lambert, E., Chopra, R., Socratous, F., Hennebry, S., et al. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328344db3a · Cited by 143
Self-citationInternational Expert Consensus Statement
Schlaich, M. P., Schmieder, R. E., Bakris, G. L., Blankestijn, P. J., Böhm, M., Campese, V. M., Francis, D. P., Grassi, G. M., Hering, D., Katholi, R. E., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.08.1616 · Cited by 143
“Nevertheless, in a report on a single patient, a progressive reduction in MSNA was obtained over time and paralleled by a reduction in BP (19).”
BackgroundSelf-citationMulder, J., Hökfelt, T., Knuepfer, M. M., & Kopp, U. C. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00599.2012 · Cited by 137
Linz, D., Hohl, M., Nickel, A. G., Mahfoud, F., Wagner, M., Ewen, S., Schotten, U., Maack, C., WIRTH, K. J., & Böhm, M. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01728 · Cited by 144
Systemic and Renal-Specific Sympathoinhibition in Obesity Hypertension
Lohmeier, T. E., Iliescu, R., Liu, B., Henegar, J. R., Maric-Bilkan, C., & Irwin, E. D. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.185074 · Cited by 130
Ukena, C., Mahfoud, F., Spies, A., Kindermann, I., Linz, D., Cremers, B., Laufs, U., Neuberger, H., & Böhm, M. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.07.027 · Cited by 134
“RDN has been shown to reduce renal and whole-body sympathetic activity and thereby blood pressure and improve glucose metabolism in patients with resistant hypertension [10,12,17–19].”
BackgroundEsler, M. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.06.001 · Cited by 133
Self-citationA novel method of selective ablation of afferent renal nerves by periaxonal application of capsaicin
Foss, J. D., Wainford, R. D., Engeland, W. C., Fink, G. D., & Osborn, J. W. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00427.2014 · Cited by 125
The sympathetic nervous system through the ages: from Thomas Willis to resistant hypertension
Esler, M. (2011) · Experimental Physiology · doi:10.1113/expphysiol.2010.052332 · Cited by 126
Self-citationRafiq, K., Noma, T., Fujisawa, Y., Ishihara, Y., Arai, Y., Nabi, A. H. M. N., Suzuki, F., Nagai, Y., Nakano, D., Hitomi, H., et al. (2012) · Circulation · doi:10.1161/circulationaha.111.064097 · Cited by 125
Novel therapeutic targets for hypertension
Paulis, L., & Unger, T. (2010) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.85 · Cited by 132
“Additionally, Schlaich and colleagues reported the case of a patient with uncontrolled hypertension in whom renal ablation reduced left ventricular hypertrophy in addition to sympathetic tone and blood pressure”
BackgroundDevice-based therapies for arterial hypertension
Lauder, L., Azizi, M., Kirtane, A. J., Böhm, M., & Mahfoud, F. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0364-1 · Cited by 132
Sympathetic nervous system: role in hypertension and in chronic kidney disease
Grassi, G., Bertoli, S., & Seravalle, G. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32834db45d · Cited by 118
Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation
Mahfoud, F., Townsend, R. R., Kandzari, D. E., Kario, K., Schmieder, R. E., Tsioufis, K., Pocock, S., David, S., Patel, K., Rao, A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.044 · Cited by 115
Sympathoneural and Adrenomedullary Responses to Mental Stress
Carter, J. R., & Goldstein, D. S. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c140030 · Cited by 102
Chinushi, M., Izumi, D., Iijima, K., Suzuki, K., Furushima, H., Saitoh, O., Furuta, Y., Aizawa, Y., & Iwafuchi, M. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.00095 · Cited by 111
Role of chemoreception in cardiorespiratory acclimatization to, and deacclimatization from, hypoxia
Dempsey, J. A., Powell, F. L., Bisgard, G. E., Blain, G. M., Poulin, M. J., & Smith, C. A. (2013) · Journal of Applied Physiology · doi:10.1152/japplphysiol.01126.2013 · Cited by 115
Linz, D., Mahfoud, F., Schotten, U., Ukena, C., Hohl, M., Neuberger, H., WIRTH, K. J., & Böhm, M. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.00182 · Cited by 108
Renal Denervation in Moderate Treatment-Resistant Hypertension
Ott, C., Mahfoud, F., Schmid, A., Ditting, T., Sobotka, P. A., Veelken, R. A., Spies, A., Ukena, C., Laufs, U., Uder, M., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.023 · Cited by 99
“Renal denervation (RDN) has emerged as an interventional approach to treat severe TRH by altering sympathetic afferent and efferent nerve activity (6).”
BackgroundSelf-citationSteigerwald, K., Titova, A., Malle, C., Kennerknecht, E., Jilek, C., Hausleiter, J., Nährig, J., Laugwitz, K., & Joner, M. (2012) · Journal of Hypertension · doi:10.1097/hjh.0b013e32835821e5 · Cited by 98
Renal Nerves and Long‐Term Control of Arterial Pressure
Osborn, J. W., & Foss, J. D. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c150047 · Cited by 93
Lambert, É., & Lambert, G. W. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0186-y · Cited by 104
“Treatment was associated with substantial and sustained reductions in blood pressure, renal norepinephrine spillover, and muscle sympathetic activity [ 48 ].”
BackgroundArmaganijan, L., Staico, R., Moreira, D. A. R., Lópes, R. D., Medeiros, P. T. J., Habib, R. G., Neto, J. M., Katz, M., Armaganijan, D., Sousa, A. G. M. R., et al. (2015) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2015.03.012 · Cited by 92
“sympathetic denervation (RSD) has been shown to decrease sympathetic activity (9) and thereby lower office and ambulatory blood pressure in certain patients with resistant hypertension for up to 3 years of follow-up (10,11).”
BackgroundThe Role of Renal Denervation in the Treatment of Heart Failure
Sobotka, P. A., Krum, H., Böhm, M., Francis, D. P., & Schlaich, M. P. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0258-x · Cited by 92
Self-citationRenal Denervation: Ultima Ratio or Standard in Treatment-Resistant Hypertension
Persu, A., Renkin, J., Thijs, L., & Staessen, J. A. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.195263 · Cited by 88
“Blood Pressure Measurement Compared with office measurement, ambulatory blood pressure monitoring removes observer bias and measurement error, minimizes the white coat effect and has greater reproducibility, and, therefore, provides a better estimate of a patient’s usual blood pressure and cardiovascular prognosis.(17…”
BackgroundObstructive sleep apnea syndrome as a cause of resistant hypertension
Parati, G., Ochoa, J. E., Bilo, G., Mattaliano, P., Salvi, P., Kario, K., & Lombardi, C. (2014) · Hypertension Research · doi:10.1038/hr.2014.80 · Cited by 98
Therapeutic strategies for targeting excessive central sympathetic activation in human hypertension
Fisher, J. P., & Fadel, P. J. (2010) · Experimental Physiology · doi:10.1113/expphysiol.2009.047332 · Cited by 94
“This quite remarkable reduction in sympathetic neural activity of ∼66% is perhaps indicative of the beneficial consequents of disruption of renal afferent signalling to the central nervous system (Schlaich et al. 2009).”
BackgroundPersistence of muscle sympathetic nerve activity during vasovagal syncope
Vaddadi, G., Esler, M. D., Dawood, T., & Lambert, E. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq071 · Cited by 84
Self-citationKario, K., Bhatt, D. L., Kandzari, D. E., Brar, S., Flack, J. M., Gilbert, C., Oparil, S., Robbins, M., Townsend, R. R., & Bakris, G. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0035 · Cited by 84
Renal Denervation for Hypertension
Bertog, S. C., Sobotka, P. A., & Sievert, H. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2011.12.011 · Cited by 96
Self-citationZuern, C. S., Eick, C., Rizas, K. D., Bauer, S., Langer, H. F., Gawaz, M., & Bauer, A. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.046 · Cited by 87
Schlaich, M. P., Hering, D., Sobotka, P., Krum, H., Lambert, G. W., Lambert, E., & Esler, M. D. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00010 · Cited by 80
“…models of various conditions characterized by heightened sympathetic drive and consistently demonstrated the importance of renal efferent and afferent nerves and their contribution to the pathophysiology of hypertension, heart failure, and chronic kidney disease (Schlaich et al., 2009b).”
BackgroundInfluentialSelf-citationLambert, G. W., Hering, D., Esler, M. D., Marusic, P., Lambert, E. A., Tanamas, S. K., Shaw, J., Krum, H., Dixon, J. B., Barton, D. A., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.200865 · Cited by 80
Self-citationOsborn, J. W., Fink, G. D., & Kuroki, M. T. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0188-9 · Cited by 82
Renal sympathetic denervation: applications in hypertension and beyond
Böhm, M., Linz, D., Urban, D., Mahfoud, F., & Ukena, C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.89 · Cited by 79
Téllez, A., Rousselle, S. D., Palmieri, T., Rate, W. R., Wicks, J. R., Degrange, A., Hyon, C. M., Gongora, C. A., Hart, R., Grundy, W., et al. (2013) · Translational research · doi:10.1016/j.trsl.2013.07.002 · Cited by 76
Grassi, G., Seravalle, G., Brambilla, G., Trabattoni, D., Cuspidi, C., Corso, R., Pieruzzi, F., Genovesi, S., Stella, A., Facchetti, R., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.04823 · Cited by 74
“An analysis was also made of BP and MSNA data from 2 subgroups of resistant hypertensive patients, which were separately considered based on (1) an office systolic BP response 6 months after renal denervation above or below the median value and (2) a MSNA response 6 months after renal denervation above or below the me…”
BackgroundMethodInfluentialFengler, K., Ewen, S., Höllriegel, R., Rommel, K., Kulenthiran, S., Lauder, L., Cremers, B., Schuler, G., Linke, A., Böhm, M., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.006196 · Cited by 75
Renal nerve ablation reduces augmentation index in patients with resistant hypertension
Hering, D., Lambert, É., Marušić, P., Sari, C. I., Walton, A., Krum, H., Sobotka, P. A., Mahfoud, F., Böhm, M., Lambert, G. W., et al. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283622e58 · Cited by 82
Self-citationNon-pharmacological modulation of the autonomic tone to treat heart failure
Singh, J. P., Kandala, J., & John Camm, A. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht436 · Cited by 73
Device-Based Neuromodulation for Resistant Hypertension Therapy: Too Early for Prime Time?
Lohmeier, T. E., & Hall, J. E. (2019) · Circulation Research · doi:10.1161/circresaha.118.313221 · Cited by 76
Physiology in Medicine: Peripheral arterial disease
Muller, M. D., Reed, A. B., Leuenberger, U. A., & Sinoway, L. I. (2013) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00885.2013 · Cited by 82
“The contribution of renal sympathetic nerves to this process in humans is an area of active investigation (74).”
BackgroundPeripheral cardiac sympathetic hyperactivity in cardiovascular disease: role of neuropeptides
Shanks, J. A., & Herring, N. (2013) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00118.2013 · Cited by 73
The Sympathetic Nervous System in Hypertension: Roadmap Update of a Long Journey
Grassi, G. M. (2021) · American Journal of Hypertension · doi:10.1093/ajh/hpab124 · Cited by 72
“3,23 More direct information on the patterns of the SNS in resistant hypertension come from data collected by our group in the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) project, an epidemiological study carried out in a large sample of the general population living in the…”
MethodChen, W., Ling, Z., Xu, Y., Liu, Z., Su, L., Du, H., Xiao, P., Lan, X., Shan, Q., & Yin, Y. (2017) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26475 · Cited by 66
McLellan, A. J. A., Schlaich, M. P., Taylor, A. J., Prabhu, S., Hering, D., Hammond, L. J., Marušić, P., Duval, J., Sata, Y., Ellims, A., et al. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.01.039 · Cited by 73
Self-citation
Metadata
- Authors
- Schlaich, M. P., Sobotka, P. A., Krum, H., Lambert, E., & Esler, M. D.
- Affiliations
- Baker Heart and Diabetes Institute (AU)
- University of Oklahoma Health Sciences Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-08-27
- Volume
- 361
- Issue
- 9
- Pages
- 932-934
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1994487234
- Cited by
- 772
- References
- 5
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 19 · 2023: 25 · 2022: 22 · 2021: 19 · 2020: 19 · 2019: 27 · 2018: 31 · 2017: 42 · 2016: 42 · 2015: 52 · 2014: 115 · 2013: 136 · 2012: 95
- FWCI
- 42.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- uncontrolled hypertension, bevacizumab, hereditary hemorrhagic telangiectasia, pulmonary arteriovenous malformation, intermittent dosing, long-term drug safety, iron requirements
- MeSH terms
- Humans, Hypertension, Kidney, Male, Middle Aged, Norepinephrine, Renal Artery, Sympathectomy, Catheter Ablation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.